New York, January 6, 2026, 09:49 EST — Regular session
- Alumis shares more than doubled after Phase 3 ONWARD trials met all main goals in plaque psoriasis
- Company said about 65% of patients reached PASI 90 and over 40% reached complete clearance at week 24
- Traders are weighing durability, safety and the path to an FDA filing planned for the second half of 2026
Alumis Inc (ALMS) shares jumped about 129% in early trade on Tuesday after the drugmaker reported positive late-stage data for its psoriasis pill, envudeucitinib. The stock was at $19.04, up from a previous close of $8.31, after touching $22.30 to set a new 52-week high, Google Finance data showed.
The readout is a pivotal moment for the South San Francisco-based biopharma, which is trying to deliver biologic-like skin clearance in a pill. A clean Phase 3 package can pull forward the regulatory clock and reset expectations for the company’s value.
Plaque psoriasis is a chronic, immune-driven disease that causes red, scaly patches on the skin and can disrupt daily life. Investors are now focused on whether envudeucitinib’s high-end clearance rates hold up over time and whether side effects stay manageable as use broadens.
Envudeucitinib met the co-primary endpoints in the Phase 3 ONWARD1 and ONWARD2 trials — PASI 75, a 75% improvement on the Psoriasis Area and Severity Index, and sPGA 0/1, meaning clear or almost clear — at week 16, Alumis said in an SEC filing. About 65% of patients achieved PASI 90 and more than 40% reached PASI 100, or complete clearance, at week 24, while the drug also beat placebo and apremilast; the company reported no new safety signals and said common side effects included headaches and upper respiratory tract infections. Chief medical officer Jörn Drappa called the data “the full promise of TYK2 inhibition,” dermatologist Andrew Blauvelt said they point to “a new oral drug for psoriasis,” and CEO Martin Babler branded it a “pipeline-in-a-pill.” SEC
Even with a sharp pop, the next debate is less about the headline endpoints and more about what the full dataset says on durability, safety and patient-reported relief. Those details can matter as much as clearance rates once payers and doctors start comparing pills side by side.
If approved, envudeucitinib would compete with Bristol Myers Squibb’s Sotyktu, another TYK2 inhibitor for psoriasis, after the trials also showed the Alumis drug outperformed Amgen’s oral therapy Otezla, Reuters reported. Leerink Partners analyst Thomas Smith said envudeucitinib offers “potential for class-leading TYK2 inhibition” and efficacy approaching that of top-selling injectable drugs. Reuters
But late-stage wins do not guarantee a smooth review or a clean launch. Regulators can push back on safety, and tough competition can squeeze pricing and limit how quickly new drugs win formulary access.
